319 related articles for article (PubMed ID: 33741670)
1. Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial.
Castillo G; Lalu MM; Asad S; Foster M; Kekre N; Fergusson DA; Hawrysh T; Atkins H; Thavorn K; Montroy J; Schwartz S; Holt RA; Broady R; Presseau J
BMJ Open; 2021 Mar; 11(3):e043929. PubMed ID: 33741670
[TBL] [Abstract][Full Text] [Related]
2. Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study.
Castillo G; Lalu M; Asad S; Foster M; Kekre N; Fergusson D; Hawrysh T; Atkins H; Thavorn K; Montroy J; Schwartz S; Holt R; Broady R; Presseau J;
Trials; 2021 Mar; 22(1):230. PubMed ID: 33766105
[TBL] [Abstract][Full Text] [Related]
3. What are potential barriers and enablers to patient and physician participation in Canadian cell therapy trials for stroke? A stakeholder interview study.
Lalu MM; Foster M; Presseau J; Dowlatshahi D; Castillo G; Cardenas A; Tam W; Zlepnig J; Timpson D; Dong YY; Juneau P; Fergusson DA
BMJ Open; 2020 Mar; 10(3):e034354. PubMed ID: 32198301
[TBL] [Abstract][Full Text] [Related]
4. Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design.
Fyfe R; Anstis O; Kapadia K; Jordan M; Sword DO; Weinkove R
BMJ Open; 2024 Jan; 14(1):e071112. PubMed ID: 38262637
[TBL] [Abstract][Full Text] [Related]
5. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
6. Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions.
Jenei K; Burgess M; Peacock S; Raymakers AJN
J Cancer Policy; 2021 Dec; 30():100303. PubMed ID: 35559799
[TBL] [Abstract][Full Text] [Related]
7. Results from a Theory-Guided Survey to Support Breast Cancer Trial Participation: Barriers, Enablers, and What to Do about them.
Brehaut JC; Carroll K; Gordon J; Presseau J; Richards DP; Fergusson DA; Graham ID; Marlin S
Curr Oncol; 2021 May; 28(3):2014-2028. PubMed ID: 34073279
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. A patient-focused, theory-guided approach to survey design identified barriers to and drivers of clinical trial participation.
Brehaut JC; Carroll K; Presseau J; Richards DP; Gordon J; Bénard A; Hudek N; Graham ID; Fergusson DA; Marlin S
J Clin Epidemiol; 2021 Apr; 132():106-115. PubMed ID: 33338563
[TBL] [Abstract][Full Text] [Related]
11. Bladder-sparing Radiotherapy for Muscle-invasive Bladder Cancer: A Qualitative Study to Identify Barriers and Enablers.
Walker M; Doiron RC; French SD; Feldman-Stewart D; Siemens DR; Mackillop WJ; Booth CM
Clin Oncol (R Coll Radiol); 2017 Dec; 29(12):818-826. PubMed ID: 28951003
[TBL] [Abstract][Full Text] [Related]
12. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
13. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials.
Raymakers AJN; Regier DA; Peacock SJ; Freeman CL
J Cancer Policy; 2021 Dec; 30():100304. PubMed ID: 35559800
[TBL] [Abstract][Full Text] [Related]
15. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T.
Akinola IM; Cusatis R; Pasquini MC; Shaw BE; Bollu V; Dalal A; Tesfaye M; Flynn KE
Transplant Cell Ther; 2023 Apr; 29(4):254.e1-254.e9. PubMed ID: 36634738
[TBL] [Abstract][Full Text] [Related]
16. What influences allied health clinician participation in research in the public hospital setting: a qualitative theory-informed approach.
Wenke R; Noble C; Weir KA; Mickan S
BMJ Open; 2020 Aug; 10(8):e036183. PubMed ID: 32819986
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
18. Improving computerized decision support system interventions: a qualitative study combining the theoretical domains framework with the GUIDES Checklist.
Yamada J; Kouri A; Simard SN; Lam Shin Cheung J; Segovia S; Gupta S
BMC Med Inform Decis Mak; 2023 Oct; 23(1):226. PubMed ID: 37853386
[TBL] [Abstract][Full Text] [Related]
19. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ
Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012
[TBL] [Abstract][Full Text] [Related]
20. "How do I keep this live in my mind?" Allied Health Professionals' perspectives of barriers and enablers to implementing good clinical practice principles in research: a qualitative exploration.
Wenke R; Roberts S; Angus R; Owusu MA; Weir K
BMC Health Serv Res; 2023 Mar; 23(1):309. PubMed ID: 36998032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
